{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:08Z","timestamp":1787988008041,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222034;W2511085"],"award-info":[{"award-number":["82222034;W2511085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Youth Scholar Program","award":["Beijing Youth Scholar Program"],"award-info":[{"award-number":["Beijing Youth Scholar Program"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-004, 2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-C-004, 2022-PUMCH-D-002"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-2-002, 2021-I2M-1-016"],"award-info":[{"award-number":["2022-I2M-2-002, 2021-I2M-1-016"]}]},{"DOI":"10.13039\/100001234","name":"Robert and Janice McNair Foundation","doi-asserted-by":"publisher","award":["Robert and Janice McNair Foundation"],"award-info":[{"award-number":["Robert and Janice McNair Foundation"]}],"id":[{"id":"10.13039\/100001234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07993-1","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:28:45Z","timestamp":1781584125000},"page":"6473-6489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7677","authenticated-orcid":false,"given":"Li\u2019ao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-7136","authenticated-orcid":false,"given":"Deling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"7993_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"7993_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/neuonc\/noy202","volume":"21","author":"MW Kieran","year":"2019","unstructured":"Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019;21:537\u201346. https:\/\/doi.org\/10.1093\/neuonc\/noy202.","journal-title":"Neuro Oncol"},{"key":"7993_CR3","doi-asserted-by":"publisher","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14:eabn1128. https:\/\/doi.org\/10.1126\/scitranslmed.abn1128.","journal-title":"Sci Transl Med"},{"key":"7993_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024;390:1290\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2314390.","journal-title":"N Engl J Med"},{"key":"7993_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","volume":"14","author":"M Westphal","year":"2013","unstructured":"Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:823\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(13)70274-2.","journal-title":"Lancet Oncol"},{"key":"7993_CR6","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1073\/pnas.1304504110","volume":"110","author":"J Zhou","year":"2013","unstructured":"Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, et al. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 2013;110:11751\u20136. https:\/\/doi.org\/10.1073\/pnas.1304504110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7993_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae125","author":"M Weller","year":"2024","unstructured":"Weller M, Albert NL, Galldiks N, Bink A, Preusser M, Sulman EP, et al. Targeted radionuclide therapy for gliomas: emerging clinical trial landscape. Neuro Oncol. 2024. https:\/\/doi.org\/10.1093\/neuonc\/noae125.","journal-title":"Neuro Oncol"},{"key":"7993_CR8","doi-asserted-by":"publisher","first-page":"1085245","DOI":"10.3389\/fmed.2022.1085245","volume":"9","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J, Morgenstern A, Pe\u0142ka K, Bruchertseifer F, Kr\u00f3licki L. Targeted alpha therapy for glioblastoma. Front Med (Lausanne). 2022;9:1085245. https:\/\/doi.org\/10.3389\/fmed.2022.1085245.","journal-title":"Front Med (Lausanne)"},{"key":"7993_CR9","doi-asserted-by":"publisher","first-page":"vdae130","DOI":"10.1093\/noajnl\/vdae130","volume":"6","author":"J Pichler","year":"2024","unstructured":"Pichler J, Traub-Weidinger T, Spiegl K, Imamovic L, Braat A, Snijders TJ, et al. Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([(131)I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1). Neurooncol Adv. 2024;6:vdae130. https:\/\/doi.org\/10.1093\/noajnl\/vdae130.","journal-title":"Neurooncol Adv"},{"key":"7993_CR10","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1097\/rlu.0000000000003142","volume":"45","author":"A Kumar","year":"2020","unstructured":"Kumar A, Ballal S, Yadav MP, ArunRaj ST, Haresh KP, Gupta S, et al. 177Lu-\/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. Clin Nucl Med. 2020;45:e512\u20133. https:\/\/doi.org\/10.1097\/rlu.0000000000003142.","journal-title":"Clin Nucl Med"},{"key":"7993_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s13139-023-00814-5","volume":"58","author":"S Ballal","year":"2024","unstructured":"Ballal S, Yadav MP, Raju S, Roesch F, Martin M, Tripathi M, et al. [(177)Lu]Lu-DOTAGA.Glu.(FAPi)(2) Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme. Nucl Med Mol Imaging. 2024;58:32\u20134. https:\/\/doi.org\/10.1007\/s13139-023-00814-5.","journal-title":"Nucl Med Mol Imaging"},{"key":"7993_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00259-022-05982-8","volume":"50","author":"L Lucaroni","year":"2023","unstructured":"Lucaroni L, Georgiev T, Prodi E, Puglioli S, Pellegrino C, Favalli N, et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2023;50:957\u201361. https:\/\/doi.org\/10.1007\/s00259-022-05982-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7993_CR13","doi-asserted-by":"publisher","first-page":"40391","DOI":"10.1021\/acsami.4c07850","volume":"16","author":"X Zhao","year":"2024","unstructured":"Zhao X, Jakobsson V, Tao Y, Zhao T, Wang J, Khong PL, et al. Targeted Radionuclide Therapy in Glioblastoma. ACS Appl Mater Interfaces. 2024;16:40391\u2013410. https:\/\/doi.org\/10.1021\/acsami.4c07850.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7993_CR14","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.7150\/thno.25599","volume":"8","author":"D Li","year":"2018","unstructured":"Li D, Zhang J, Chi C, Xiao X, Wang J, Lang L, et al. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using (68)Ga-IRDye800CW-BBN. Theranostics. 2018;8:2508\u201320. https:\/\/doi.org\/10.7150\/thno.25599.","journal-title":"Theranostics"},{"key":"7993_CR15","doi-asserted-by":"publisher","first-page":"e10182","DOI":"10.1002\/btm2.10182","volume":"6","author":"K He","year":"2021","unstructured":"He K, Chi C, Li D, Zhang J, Niu G, Lv F, et al. Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery. Bioeng Transl Med. 2021;6:e10182. https:\/\/doi.org\/10.1002\/btm2.10182.","journal-title":"Bioeng Transl Med"},{"key":"7993_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2967\/jnumed.115.165316","volume":"57","author":"J Zhang","year":"2016","unstructured":"Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, et al. 68Ga-NOTA-Aca-BBN(7\u201314) PET\/CT in Healthy Volunteers and Glioma Patients. J Nucl Med. 2016;57:9\u201314. https:\/\/doi.org\/10.2967\/jnumed.115.165316.","journal-title":"J Nucl Med"},{"key":"7993_CR17","doi-asserted-by":"publisher","first-page":"e10532","DOI":"10.1002\/btm2.10532","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang L, Zhang C, Zhang J, Yuan L, Jin S, et al. Preclinical assessment of IRDye800CW-labeled gastrin-releasing peptide receptor-targeting peptide for near infrared-II imaging of brain malignancies. Bioeng Transl Med. 2023;8:e10532. https:\/\/doi.org\/10.1002\/btm2.10532.","journal-title":"Bioeng Transl Med"},{"key":"7993_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-025-01198-7","volume":"15","author":"Y Li","year":"2025","unstructured":"Li Y, Wang R, Chen J, Zhu Z, Wang Y, Ma W. (68)Ga-NOTA-RM26 PET\/CT in the evaluation of glioma: a pilot prospective study. EJNMMI Res. 2025;15:6. https:\/\/doi.org\/10.1186\/s13550-025-01198-7.","journal-title":"EJNMMI Res"},{"key":"7993_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005651","author":"R Wang","year":"2025","unstructured":"Wang R, Li Y, Li Z, Wang J, Li L, Xiang J, et al. Gastrin-Releasing Peptide Receptor Targeting PET\/CT With 68Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies. Clin Nucl Med. 2025. https:\/\/doi.org\/10.1097\/RLU.0000000000005651.","journal-title":"Clin Nucl Med"},{"key":"7993_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7150\/thno.91554","volume":"14","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang J, Chi C, Che W, Dong G, Wang J, et al. Lower-grade gliomas surgery guided by GRPR-targeting PET\/NIR dual-modality image probe: a prospective and single-arm clinical trial. Theranostics. 2024;14:819\u201329. https:\/\/doi.org\/10.7150\/thno.91554.","journal-title":"Theranostics"},{"key":"7993_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/RLU.0000000000005651","volume":"50","author":"R Wang","year":"2025","unstructured":"Wang R, Li Y, Li Z, Wang J, Li L, Xiang J, et al. Gastrin-Releasing Peptide Receptor Targeting PET\/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies. Clin Nucl Med. 2025;50:316\u201323. https:\/\/doi.org\/10.1097\/RLU.0000000000005651.","journal-title":"Clin Nucl Med"},{"key":"7993_CR22","doi-asserted-by":"publisher","unstructured":"Clark AJ, Fakurnejad S, Ma Q, Hashizume R. Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. J Vis Exp. 2016;e53287. https:\/\/doi.org\/10.3791\/53287.","DOI":"10.3791\/53287"},{"key":"7993_CR23","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/ijc.32401","volume":"145","author":"B Mitran","year":"2019","unstructured":"Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, et al. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG(2) -RM26. Int J Cancer. 2019;145:3347\u201358. https:\/\/doi.org\/10.1002\/ijc.32401.","journal-title":"Int J Cancer"},{"key":"7993_CR24","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18:e3000411. https:\/\/doi.org\/10.1371\/journal.pbio.3000411.","journal-title":"PLoS Biol"},{"key":"7993_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","volume":"11","author":"JG Nicholson","year":"2021","unstructured":"Nicholson JG, Fine HA. Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discov. 2021;11:575\u201390. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1474.","journal-title":"Cancer Discov"},{"key":"7993_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7993_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"7993_CR28","doi-asserted-by":"publisher","first-page":"105202","DOI":"10.1016\/j.ebiom.2024.105202","volume":"105","author":"L Roncali","year":"2024","unstructured":"Roncali L, Marionneau-Lambot S, Roy C, Eychenne R, Gouard S, Avril S, et al. Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice. EBioMedicine. 2024;105:105202. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105202.","journal-title":"EBioMedicine"},{"key":"7993_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/RLU.0000000000004608","volume":"48","author":"L Krolicki","year":"2023","unstructured":"Krolicki L, Kunikowska J, Bruchertseifer F, Kulinski R, Pawlak D, Koziara H, et al. Locoregional Treatment of Glioblastoma With Targeted alpha Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters. Clin Nucl Med. 2023;48:387\u201392. https:\/\/doi.org\/10.1097\/RLU.0000000000004608.","journal-title":"Clin Nucl Med"},{"key":"7993_CR30","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","volume":"48","author":"L Kr\u00f3licki","year":"2021","unstructured":"Kr\u00f3licki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kuli\u0144ski R, et al. Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy. Eur J Nucl Med Mol Imaging. 2021;48:3595\u2013605. https:\/\/doi.org\/10.1007\/s00259-021-05350-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7993_CR31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"TAT Working","year":"2018","unstructured":"Working TAT, Parker G, Lewington C, Shore V, Kratochwil N, Levy C. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol. 2018;4:1765\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044.","journal-title":"JAMA Oncol"},{"key":"7993_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/btt.S29947","volume":"8","author":"BJ Allen","year":"2014","unstructured":"Allen BJ, Huang CY, Clarke RA. Targeted alpha anticancer therapies: update and future prospects. Biologics. 2014;8:255\u201367. https:\/\/doi.org\/10.2147\/btt.S29947.","journal-title":"Biologics"},{"key":"7993_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainresbull.2010.02.014","volume":"82","author":"DG Flores","year":"2010","unstructured":"Flores DG, Meurer L, Uberti AF, Macedo BR, Lenz G, Brunetto AL, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010;82:95\u20138. https:\/\/doi.org\/10.1016\/j.brainresbull.2010.02.014.","journal-title":"Brain Res Bull"},{"key":"7993_CR34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1021\/bc300206q","volume":"23","author":"JD Wilson","year":"2012","unstructured":"Wilson JD, Broaddus WC, Dorn HC, Fatouros PP, Chalfant CE, Shultz MD. Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme. Bioconjug Chem. 2012;23:1873\u201380. https:\/\/doi.org\/10.1021\/bc300206q.","journal-title":"Bioconjug Chem"},{"key":"7993_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4161\/cbt.7.3.5414","volume":"7","author":"A Casaco","year":"2008","unstructured":"Casaco A, Lopez G, Garcia I, Arsenio Rodriguez J, Fernandez R, Figueredo J, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther. 2008;7:333\u20139. https:\/\/doi.org\/10.4161\/cbt.7.3.5414.","journal-title":"Cancer Biol Ther"},{"key":"7993_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/14712598.6.5.539","volume":"6","author":"WR Shapiro","year":"2006","unstructured":"Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1\/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther. 2006;6:539\u201345. https:\/\/doi.org\/10.1517\/14712598.6.5.539.","journal-title":"Expert Opin Biol Ther"},{"key":"7993_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/neuonc\/not298","volume":"16","author":"N Luther","year":"2014","unstructured":"Luther N, Zhou Z, Zanzonico P, Cheung NK, Humm J, Edgar MA, et al. The potential of theragnostic \u00b9\u00b2\u2074I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16:800\u20136. https:\/\/doi.org\/10.1093\/neuonc\/not298.","journal-title":"Neuro Oncol"},{"key":"7993_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.117.205054","volume":"59","author":"SA Jannetti","year":"2018","unstructured":"Jannetti SA, Carlucci G, Carney B, Kossatz S, Shenker L, Carter LM, et al. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. J Nucl Med. 2018;59:1225\u201333. https:\/\/doi.org\/10.2967\/jnumed.117.205054.","journal-title":"J Nucl Med"},{"key":"7993_CR39","doi-asserted-by":"publisher","unstructured":"Li J, Dong J, Wang W, Yu D, Fan X, Hui YC et al. The human pre-replication complex is an open complex. Cell. 2023;186:98\u2013111 e21. https:\/\/doi.org\/10.1016\/j.cell.2022.12.008","DOI":"10.1016\/j.cell.2022.12.008"},{"key":"7993_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/2159-8290.CD-12-0353","volume":"3","author":"Y Ding","year":"2013","unstructured":"Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, et al. Cancer-Specific requirement for BUB1B\/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov. 2013;3:198\u2013211. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0353.","journal-title":"Cancer Discov"},{"key":"7993_CR41","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.7150\/ijbs.64003","volume":"17","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, et al. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2\/Bax pathway. Int J Biol Sci. 2021;17:3608\u201321. https:\/\/doi.org\/10.7150\/ijbs.64003.","journal-title":"Int J Biol Sci"},{"key":"7993_CR42","unstructured":"Akabani G. Reardon Da Fau - Coleman RE, Coleman Re Fau - Wong TZ, Wong Tz Fau - Metzler SD, Metzler Sd Fau - Bowsher JE, Bowsher Je Fau - Barboriak DP, Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study."},{"key":"7993_CR43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3171\/2010.2.JNS091744","volume":"113","author":"D Yin","year":"2010","unstructured":"Yin D, Richardson RM, Fiandaca MS, Bringas J, Forsayeth J, Berger MS, et al. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg. 2010;113:240\u20138. https:\/\/doi.org\/10.3171\/2010.2.JNS091744.","journal-title":"J Neurosurg"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07993-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:41Z","timestamp":1787986841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07993-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7993"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07993-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experimental protocols were approved by the Animal Care and Use Committee of Beijing Neurosurgical Institute (BNI202304003).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"XYC is a co-founder of and holds shares in Yantai Lannacheng Biotechnology Co., Ltd.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}